Monday, 26 June 2017

Generics News

  • GSK China VP confesses in bribery scandal

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 18 Jul, 2013

    Singapore: A day after Chinese police made the names of those involved in one of the country's biggest scandal involving a major pharmaceutical company public, GlaxoSmithKline China's vice ...Read more

  • India revokes Roche's cancer drug Herceptin patent

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 05 Aug, 2013

    New Delhi: In what is being criticized as yet another miserable experience created by India's intellectual property and pricing authorities for western drugmakers, the country has partly re...Read more

  • DCGI asks Wockhardt, Ranbaxy to explain lapses

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 02 Sep, 2013

    Singapore: The Indian Drug Controller General of India (DCGI) has written a letter to the drug maker Wockhardt to explain the deficiencies found at its Aurangabad manufacturing unit. The FD...Read more

  • Dr. Reddy's launches generic psychiatric drug

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 23 Aug, 2013

    Singapore: Dr. Reddy's Laboratories has launched drug for psychiatric conditions, Divalproex Sodium extended release tablets (250 mg and 500 mg). These are therapeutic equivalent generic v...Read more

  • Strides gets tentative FDA nod for HIV generic

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 02 Aug, 2013

    Singapore: FDA has granted tentative approval to India-based Strides Arcolab's HIV drug emtricitabine and tenofovir disoproxil fumarate tablets, 200 mg/300 mg. The drug is a generic versio...Read more

  • GSK hit by more bribery allegations in China

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 08 Jul, 2013

    Singapore: Days after a probe was initiated by the Chinese police into alleged 'economic crimes' committed by senior officials of GlaxoSmithKline in China, a latest news report has now rele...Read more

  • Ranbaxy launches generic of Pioglitazone in US

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 20 Aug, 2012

    Bangalore: Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, has launched authorized generic pioglitazone hydrochloride tablets in the US market, under an agreeme...Read more

  • Abbott rejigs strategy, realigns India business

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 12 Jul, 2013

    Singapore: After acquiring the formulations business of India's Piramal Healthcare in 2010, US drug major Abbott Laboratories has now revealed its new growth strategy. In an effort to boost...Read more

  • Chinese medicine firm Tianyin gets GMP certificate

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 16 Sep, 2013

    Singapore: China-based Tianyin Pharmaceutical (TPI) received GMP certification for its pre-extraction plant and formulate facilities. Tianyin Pharmaceutical is a pharmaceutical company th...Read more

  • Natco wins patent dispute case against Teva

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 04 Mar, 2014

    Singapore: Based in India's Hyderabad, drug manufacturing major Natco Pharmaceuticals has won a long standing patent dispute case against Israeli drug major Teva Pharmaceuticals. The High ...Read more

  • Lilly to expand generics manufacturing facility in China

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 06 Mar, 2014

    Singapore: Lilly and Novast Laboratories have commenced the expansion of manufacturing and development facility capacities in Nantong, Jiangsu, China. The expansion is a result of Lilly's s...Read more

  • Ranbaxy to market infliximab biosimilar

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 09 Jan, 2014

    Singapore: Switzerland based EPIRUS, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, and Ranbaxy Laboratories, a division of Daiichi Sankyo Company, Tokyo, have signed ...Read more

  • US FDA issues API bulk & tapped density guidance

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 11 Jul, 2013

    Singapore: The US Food and Drug Administration (FDA) has issued guidance to the Active Pharmaceutical ingredient industry on bulk density and tapped density of powders. The norms revolve a...Read more

  • Teva gets FDA nod for generics of Eli Lillys Evista

    Generics |  News | By BioSpectrum Bureau | 0 Comment | 05 Mar, 2014

    Singapore: Teva Pharmaceutical has recieved USFDA approval of the generic equivalent to Evista (Raloxifene) Tablets, 60 mg, in the United States. Teva was first to file, making the product ...Read more

  • Sun Pharma revenue touches $480 million in Q2 2012

    Generics |  Company results | By BioSpectrum Bureau | 0 Comment | 10 Aug, 2012

    Mumbai: Sun Pharmaceutical Industries reported a growth of 62 percent in its net sales for the quarter ending June 30, 2012, over same quarter last year. The income stood at approximately $...Read more

  • FIPB clears seven pharma proposals, defers three

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 08 Jul, 2013

    Singapore: The Foreign Investment Promotion Board (FIPB) has cleared seven out of the ten investment proposals in the pharmaceutical and biotechnology sector. At the board meeting held on F...Read more

  • Australia temporarily bans 19 synthetic drugs

    Generics |  Regulatory | By BioSpectrum Bureau | 0 Comment | 21 Jun, 2013

    Singapore: The Australian government has imposed a temporary ban on sales of 19 synthetic drugs pursuant to the product safety provisions of the Australian Consumer Law. The 120-day ban app...Read more

  • Generics market to touch $231 bn by 2017: Report

    Generics |  Analysis | By BioSpectrum Bureau | 0 Comment | 04 Jun, 2012

    Singapore: The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost ...Read more

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls